Journal
EMERGING INFECTIOUS DISEASES
Volume 27, Issue 7, Pages 1821-1830Publisher
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid2707.210462
Keywords
-
Categories
Ask authors/readers for more resources
SARS-CoV-2 emerged in late 2019, causing symptoms similar to influenza viruses. The FDA granted emergency use authorization for a multiplex assay that can detect influenza A and B viruses, as well as SARS-CoV-2, increasing testing capacity and conserving resources.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019, and the outbreak rapidly evolved into the current coronavirus disease pandemic. SARS-CoV-2 is a respiratory virus that causes symptoms similar to those caused by influenza A and B viruses. On July 2, 2020, the US Food and Drug Administration granted emergency use authorization for in vitro diagnostic use of the Influenza SARS-CoV-2 Multiplex Assay. This assay detects influenza A virus at 10(2.0), influenza B virus at 10(2.2), and SARS-CoV-2 at 10(0.3) 50% tissue culture or egg infectious dose, or as few as 5 RNA copies/reaction. The simultaneous detection and differentiation of these 3 major pathogens increases overall testing capacity, conserves resources, identifies co-infections, and enables efficient surveillance of influenza viruses and SARS-CoV-2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available